Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-02-03
1999-07-06
Degen, Nancy
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 21, 514814, 530397, 530402, 530408, 530409, 530410, 530411, A61K 3816, A61K 3822, C07K 110, C07K 14505
Patent
active
059197587
ABSTRACT:
The invention relates to novel modified polypeptides, with or without variations in noncoding regions, with altered biological activity. The invention discloses methods of preparing the modified polypeptides and methods of use.
REFERENCES:
patent: 4258193 (1981-03-01), Fujii et al.
patent: 4659839 (1987-04-01), Nicolotti et al.
patent: 4677195 (1987-06-01), Hewick et al.
patent: 4797491 (1989-01-01), Nitecki et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5024834 (1991-06-01), Houston et al.
patent: 5066490 (1991-11-01), Neville, Jr. et al.
patent: 5112615 (1992-05-01), Ho et al.
patent: 5116944 (1992-05-01), Sivam et al.
patent: 5134071 (1992-07-01), Gaetjens
patent: 5157123 (1992-10-01), Zora et al.
patent: 5241078 (1993-08-01), Moreland et al.
patent: 5260421 (1993-11-01), Chappel et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5688679 (1997-11-01), Powell
patent: 5747446 (1998-05-01), Sytkowski
Singh et al., "Comparison of the Cytotoxic Effect of Hormonotoxins Prepared with the Use of Heterobifunctional Cross-Linking Agents . . ." Bioconjug. Chem., (4)6"473-482 (1993).
Peeters et al., "Comparison of Four Bifunctional Reagents for Coupling Peptdes to Proteins . . . ", J. Immunol. Meth., 120(1):133-143 (1989).
Pierce, "Pierce 1989 Handbook & General Catalog," Pierce Europe B.V., NL, pp. 286-311.
Haniu et al., "Recombinant Human Erythropoietin (rHuEPO): Cross-Linking with Disuccinimidyl Esters and Identification of the Interfacing Domains in EPO," Protein Science 2:1441-1451 (1993).
Mayeux et al., "Structure of the Murine Erythropoietin Receptor Complex," J. Biol. Chem., 266(34):23380-23385 (1991).
Jung et al., "Crosslinking of Platelet Glycoprotein Ib by N-Succinimidyl (4-Azidophenyldiothio) Propionate and 3,3'-Dithiobis (Sulfosuccinimidyl Propionate)," Biochimica et Biophysicia Acta, 761:152-162 (1983).
Chamow et al., "Conjugation of Soluble CD4 Without Loss of Biological Activity via a Novel Carbohydrate-Directed Cross-Linking Reagent," J. Biol. Chem. 267(22):15916-15922 (1992).
Carlsson et al., "Protein Thiolation and Reversible Protein-Protein Conjugation," Biochem. J., 173:723-737 (1978).
Hashida et al., "More Useful Maleimide Compounds fo the Conjugation of Fab' to Horseradish Perioidase Through Thiol Groups in the Hinge," J. Applied Biochem. 6:56-63 (1984).
Sytkowski et al., "Isolation and Characterization of an Anti-Peptide Monoclonal Antibody to Human Erythropoietin," J. Biol. Chem., 260(27):14727-14731 (1985).
Lin et al., "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 82:7580-7584 (1985).
Krystal, G., "A Simple Microassay for Erythropoietin Based on .sup.3 H Thymidine Incorporation into Spleen Cells from Phenylhydrazine Treated Mice," Hematol. 11(7):649-660 (1983).
McDonald et al., "Cloning, Sequencing, and Evolutionary Analysis of the Mouse Erythropoeitin Gene," Mol. and Cell. Biol. 67:842-848 (1986).
Knusli et al., "Polyethylene Glycol (PEG) Modification of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Enhances Netrophil Priming Activity but Not Colony Stimulating Activity," J. of Hemat. 82:654-663 (1992).
Satake et al., "Chemical Modification of Erythropoietin: An Increase In In Vitro Activity by Guanidination," Biochimica et Biophysica Acta 1038:125-129 (1990).
Boissel et al., "Erythropoietin Structure-Function Relationships," J. Biol. Chem. 268(21):15983-15993 (1993).
Powell et al., "Human Erythropoietin Gene: High Level Expression in Stably Transfected Mammalian Cells and Chromosome Localization," Proc. Natl. Acad. Sci. USA 83:6465-6469 (1986).
Goldwasser et al., "Purification of Erythropoietin," Proc. Natl. Acad. Sci. USA 68(4):697-698 (1971).
Spivak et al., "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood 73(1):90-99 (1989).
McMahon et al., "Pharmacokinetics and Effects of Recombinant Human Erythropoietin After Intravenous and Subcutaneous Injections in Healthy Volunteers," Blood 76(9):1718-1722 (1990).
Clark et al., "Disulfide Exchange Between Insulin and its Receptor," J. Biol. Chem., 258(19):11434-11437 (1983).
Clark et al., "Insulin Binding Leads to the Formation of Covalent (--S--S--) Hormone Receptor Complexes," J. Biol. Chem., 257:12239-12344 (1982).
Miyake et al., "Purification of Human Erythropoietin," J. Bio. Chem., 252:5558-5564 (1977).
Boissel, J.P, et al., "Erythropoietin Structure-Function Relationships Mutant Proteins That Test A Model of Tertiary Structure", J. Biol. Chem., 268(21):15983-15993 (1993).
Sytkowski, A.J., et al., "Human erythropoietin dimers with markedly enhanced in vivo activity", Proc. Natl. Acad. Sci. USA 95:1184-1188 (1998) .
Beth Israel Deaconess Medical Center
Degen Nancy
LandOfFree
Modified polypeptides with altered biological activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified polypeptides with altered biological activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified polypeptides with altered biological activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-899034